Safety of synthetic trans-resveratrol as a novel food pursuant to Regulation (EC) No 258/97


Panel on Dietetic Products, Nutrition and Allergies
EFSA Journal
EFSA Journal 2016;14(1):4368 [30 pp.].
Panel members at the time of adoption
Jean Louis Bresson, Barbara Burlingame, Tara Dean, Susan Fairweather-Tait, Marina Heinonen, Karen Ildico Hirsch-Ernst, Inge Mangelsdorf, Harry McArdle, Androniki Naska, Monika Neuhäuser-Berthold, Grażyna Nowicka, Kristina Pentieva, Yolanda Sanz, Alfonso Siani, Anders Sjödin, Martin Stern, Daniel Tomé, Dominique Turck, Hendrik Van Loveren, Marco Vinceti and Peter Willatts.
The Panel wishes to thank the members of the Working Group on Novel Foods: Tara Dean, Karl-Heinz Engel, Marina Heinonen, Inge Mangelsdorf, Rosangela Marchelli, Harry McArdle, Monika Neuhäuser-Berthold, Annette Pöting, Morten Poulsen, Yolanda Sanz, Josef Schlatter and Hendrik Van Loveren for the preparatory work on this scientific opinion.
Opinion of the Scientific Committee/Scientific Panel
On request from
European Commission following an application by DSM Nutritional Products Ltd
Question Number
11 December 2015
Published in the EFSA Journal
12 January 2016
European Food Safety Authority (EFSA), Parma, Italy
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and Allergies was asked for an opinion on the safety of synthetic trans-resveratrol as a novel food with a purity of ≥99% (w/w). The Panel considers that the information provided on the composition and specifications of the novel food is sufficient. The applicant intends to market the novel food as a food supplement in capsule or tablet form at daily doses up to 150 mg/day. The Panel considers that resveratrol does not have a nutritionally relevant role in the human diet and that the consumption of the novel food is not nutritionally disadvantageous. In accordance with the EFSA Scientific opinion on genotoxicity testing strategies, the Panel considers that the negative in vivo genotoxicity assay is sufficient to rule out the concern based on the positive in vitro chromosomal aberration tests. Reduced body weight gain is seen consistently in animal studies. On the basis of the BMDL05 of 344 mg/kg body weight (bw) per day derived from body weight data of female rats in a subchronic toxicity study and the intended intake of 150 mg/day, the margin of exposure is 172. For pregnant rats, it is below 62. Considering the weight of evidence, the Panel concludes that the intended intake level of 150 mg/day for adults does not raise safety concerns. The Panel notes that diarrhoea or other gastrointestinal symptoms were reported in four uncontrolled intervention studies at doses of 1 g resveratrol/day or higher. The Panel considers that the metabolite trans-resveratrol sulfate could inhibit CYP enzymes in humans and may interact with medicines which are mainly metabolised by CYP2C9. The Panel concludes that the novel food, synthetic trans-resveratrol, is safe under the proposed conditions of use.
novel food, resveratrol, synthetic
Print on demand
Number of Pages